Trinidad-based conglomerate Agostini Limited has obtained crucial regulatory clearance from Jamaica’s Fair Trading Commission (FTC), removing the final obstacle to its acquisition of Massy Distribution (Jamaica) Limited. The landmark transaction, initially announced in February 2025, had been suspended due to antitrust concerns regarding potential market dominance in insulin distribution.
The regulatory breakthrough came after Agostini agreed to divest one of three insulin brands distributed in Jamaica, addressing the FTC’s concerns about pharmaceutical market concentration. This concession prevents the formation of a monopoly in the critical diabetes medication sector while allowing the broader acquisition to proceed.
Barry Davis, Chief Executive Officer of Agostini, emphasized the strategic importance of the Jamaican market, stating: “Jamaica remains a pivotal market for our long-term growth strategy. Our collaborative resolution with the FTC demonstrates our unwavering commitment to regulatory compliance and ethical business practices across all operating territories.”
The acquisition will be executed through Acado Limited, a joint venture equally owned by Agostini and Barbados-based Goddard Enterprises Limited. Post-acquisition, Massy Distribution’s pharmaceutical operations will integrate into Aventa Jamaica (formerly Health Brands Limited), while consumer divisions will fall under Acado’s management.
This expansion significantly enhances Agostini’s footprint in Jamaica’s pharmaceutical and consumer distribution sectors, building upon its existing presence established through the August 2023 acquisition of Aventa Jamaica. The consolidation reflects broader regional trends in distribution market integration.
For Massy Holdings Limited, the divestment represents continued strategic refocusing on core energy operations. Following the transaction, Massy’s Jamaican presence will concentrate exclusively on gas distribution through Massy Gas Products (Jamaica) Limited and IGL Limited, which maintain dominant positions in both bulk and packaged LPG markets.
Financial disclosures reveal Massy Distribution Jamaica generated TT$352.44 million in revenue for fiscal year ending September 2025, representing a 5% year-over-year decline, with net profits of TT$24.29 million. Recent quarterly performance showed further softening, attributed to Hurricane Melissa’s impact and operational stabilization efforts within gas businesses.
Despite Jamaican segment challenges, Massy’s consolidated performance improved with overall revenue increasing 6% to TT$4.39 billion and net profit from continuing operations rising 9% to TT$221.14 million.
The FTC’s conditional approval underscores increased regulatory vigilance regarding pharmaceutical distribution, particularly for essential medicines. The insulin divestment requirement establishes a precedent for intervention in healthcare market consolidation that could compromise competitive dynamics.
Market reactions showed Massy’s shares closing at $72.51 on the Jamaica Stock Exchange, reflecting a 5% decline year-to-date, while Trinidad trading saw shares at TT$3.55, down 4% for the period. The group has declared a TT$0.0354 dividend payable March 27 to shareholders of record February 27.
With regulatory barriers resolved, Agostini emerges as a strengthened competitor in Jamaica’s distribution landscape, while Massy advances its strategic pivot toward energy and industrial specialization across the Caribbean region.